Improving beta‐cell secretory function and glycemia in young‐onset type 2 diabetes: A pilot, 12‐month, randomized trial of a novel, CGM ‐guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide

Author(s):  
TL Middleton ◽  
MI Constantino ◽  
M McGill ◽  
M D'Souza ◽  
DK Yue ◽  
...  
Diabetologia ◽  
2006 ◽  
Vol 49 (8) ◽  
pp. 1876-1880 ◽  
Author(s):  
R. Singh ◽  
E. Pearson ◽  
P. J. Avery ◽  
M. I. McCarthy ◽  
J. C. Levy ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 522-P
Author(s):  
TIMOTHY MIDDLETON ◽  
STEVE CHADBAN ◽  
LYNDA M. MOLYNEAUX ◽  
MARIO I. D'SOUZA ◽  
MARIA I. CONSTANTINO ◽  
...  

2018 ◽  
Vol 72 (9) ◽  
pp. e13238
Author(s):  
Chung-Ze Wu ◽  
Jin-Sheun Chen ◽  
Yuh-Feng Lin ◽  
Chang-Hsun Hsieh ◽  
Jiunn-Diann Lin ◽  
...  

2020 ◽  
Author(s):  
Digsu N. Koye ◽  
Joanna Ling ◽  
John Dibato ◽  
Kamlesh Khunti ◽  
Olga Montvida ◽  
...  

<b>Objectives: </b>To evaluate temporal prevalence trend, cardiometabolic risk factors, and the risk of atherosclerotic cardiovascular disease (ASCVD) and all-cause mortality (ACM) in incident young- and usual-onset type 2 diabetes. <p><b>Research Design and Methods: </b>From the UK primary care database, 370,854 people with new diagnosis of type 2 diabetes from 2000 to 2017 were identified. Analyses were conducted by age groups (18-39, 40-49, 50-59, 60-69, 70-79 years) and high/low risk status without history of ASCVD at diagnosis - ≥ two of current smoking, high SBP, high LDL-C or chronic kidney disease were classified as high-risk. </p> <p><b>Results:</b> Proportion of people aged <50 years at diagnosis increased during 2000-2010 and then stabilised. The incidence rates of ASCVD and ACM declined in people aged ≥50 years, but did not decrease in people <50 years. Compared to people aged ≥50 years, those aged 18-39 years at diagnosis had higher obesity (71% obese), higher HbA1c (8.6%), 71% had high LDL-C, while only 18% were on cardio-protective therapy. Although 2% in this age group had ASCVD at diagnosis, 23% were identified as high-risk. In the 18-39 years group, the adjusted average years to ASCVD /ACM in high-risk individuals (years (95% CI): 9.1 (8.2–10.0) /9.3 (8.1–10.4)) were similar to those with low-risk (years (95% CI): 10.0 (9.5 – 10.5) /10.5 (9.7–11.2)). However, individuals ≥50 years with high-risk were likely to experience an ASCVD event 1.5 - 2 years earlier and death 1.1 – 1.5 years earlier compared to low-risk groups (p<0.01). </p> <p><b>Conclusions: </b>Unlike usual-onset,<b> </b>young-onset type 2 diabetes have similar cardiovascular and mortality risk irrespective of their cardiometabolic risk factor status at diagnosis. The guidelines on the management of young-onset type 2 diabetes for intensive risk-factor management and cardioprotective therapies need to be urgently re-evaluated through prospective studies.<b> </b></p>


2014 ◽  
Vol 236 (2) ◽  
pp. 286-291 ◽  
Author(s):  
Jian-Jun Liu ◽  
Chee Fang Sum ◽  
Subramaniam Tavintharan ◽  
Lee Ying Yeoh ◽  
Xiao Wei Ng ◽  
...  

2017 ◽  
Vol 6 (2) ◽  
pp. 110-113
Author(s):  
Yassamine Bentata ◽  
Redouane Abouqal

2020 ◽  
Vol 37 (6) ◽  
pp. 991-999
Author(s):  
T. L. Middleton ◽  
M. I. Constantino ◽  
L. Molyneaux ◽  
M. D'Souza ◽  
S. M. Twigg ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document